Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03901235 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MSC Intratissular Injection in Crohn Disease Patients

Study acronym: MSC
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 12, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revisedv6
  2. Primary completion date: Dec 31, 2022 to Dec 31, 2025
    • Study completion date: Dec 31, 2023 to Dec 31, 2026
    v5
  3. Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Study completion date: Dec 31, 2022 to Dec 31, 2023
    v4
  4. Primary completion date: Dec 31, 2020 to Dec 31, 2021
    • Study completion date: Dec 31, 2021 to Dec 31, 2022
    v3
  5. Primary completion date: Apr 1, 2019 to Dec 31, 2020
    • Study completion date: Apr 1, 2020 to Dec 31, 2021
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective is to assess the efficacy of local injection of MSC on the healing of refractory intestinal and perianal lesions in crohn disease. The second co-primary endpoint is safety.
Trial Details
NCT Number NCT03901235
Lead Sponsor University of Liege
Collaborators: Centre Hospitalier Universitaire de Liege
Conditions
(from sponsor)		 Efficacy and Safety
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov